What Percentage of People Lose Weight on Ozempic?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has transformed weight loss outcomes for millions of people worldwide. Research published in medical journals shows that roughly 60–80% of individuals using semaglutide achieve meaningful weight reduction, with many losing 10–15% of their starting body weight within six months. PlexusDx delivers compounded semaglutide through licensed pharmacies to all 50 states, making this evidence-based therapy accessible without insurance or membership fees.

Clinical Weight Loss Rates for Semaglutide Users

Landmark trials demonstrate that semaglutide produces weight loss in the majority of patients who use it consistently. In the STEP trials (Semaglutide Treatment Effect in People with Obesity), participants taking semaglutide lost an average of 10–15% of their body weight, compared to 2–3% in placebo groups. These results held across diverse age groups, BMI ranges, and metabolic profiles, suggesting broad effectiveness across different patient populations.

Not every person responds identically to semaglutide. Success depends on dose escalation, adherence to the medication schedule, dietary choices, physical activity level, and individual metabolic factors. Most users see measurable results within 4–8 weeks of starting therapy, though peak weight loss typically occurs between months 4–6 of consistent use. Individual variation is normal and expected.

Why Some People Lose More Weight Than Others

Semaglutide works by activating GLP-1 receptors in your brain and gut, signaling fullness and reducing hunger. However, genetic differences in the GLP1R gene and other metabolic pathways influence how effectively your body responds to these signals. Some people carry genetic variants that amplify the medication's effect, while others may need higher doses or different compounds to achieve optimal results.

PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 49 peptides tied to weight loss response, including key variants like FTO rs9939609. This personalized approach helps identify whether standard semaglutide suits you best, or whether another therapy—such as tirzepatide or a dual-compound option—might deliver faster results. Testing costs $298.

Compounded Semaglutide vs. Brand-Name Ozempic

PlexusDx sources semaglutide from licensed 503A compounding pharmacies, which manufacture medications to the same specifications as commercial pharmaceuticals but at a fraction of the cost. Compounded semaglutide has the same active ingredient and potency as brand-name Ozempic, though it is not FDA-approved as a finished product. Clinical outcomes and side-effect profiles are consistent between compounded and brand-name formulations.

The key difference is affordability and accessibility. A month of PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), with no insurance required and HSA/FSA eligibility. This price holds steady regardless of your dose—your dose may need to go up as your body adjusts, but your monthly cost remains flat. For patients without insurance or facing high copays, compounded therapy from PlexusDx removes financial barriers to treatment.

Expected Timeline and Managing Expectations

Most people notice reduced appetite and increased fullness within the first 1–2 weeks of starting semaglutide injections. Measurable weight loss typically appears by week 3–4, though the scale may fluctuate slightly as your body adapts. Consistent use over 12 weeks yields the most reliable results, with peak weight loss occurring around month 5–6 of therapy.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of people actually lose weight on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How much weight can I expect to lose on semaglutide?

Average weight loss ranges from 10–15% of starting body weight over six months in clinical trials. Some people lose 20% or more, while others lose 5–10%. Your genetics, diet, exercise, and how consistently you take the medication all influence your final outcome.

Is compounded semaglutide from PlexusDx as effective as Ozempic?

Yes. PlexusDx compounded semaglutide contains the identical active ingredient and potency as brand-name Ozempic, sourced from licensed 503A compounding pharmacies. Clinical outcomes and side-effect profiles are equivalent; the difference is cost and convenience.

How much does semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan and remain flat regardless of your dose. No insurance, membership fee, or subscription commitment is required. HSA and FSA funds are accepted.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights related to appetite, satiety, and nutrient processing. It cannot guarantee exact outcomes but can reveal whether you carry genetic variants associated with stronger GLP-1 response, higher FTO risk, or better MC4R signaling. Results help PlexusDx providers optimize your starting compound and dosing strategy.

Related Reading

• Ozempic For Losing Weight
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.